Additional file 1: of The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial

SPIRIT checklist. (DOC 293 kb

Adapted path model including the DACC score as an independent variable predicting high on treatment platelet reactivity (HTPR); Age and HTPR as independent predictors of major adverse cardiac events (MACE: the composite of acute coronary syndrome, stent thrombosis and cardiac death).

<p>Paths from independent to dependent variables represent standardized estimates. *p<0.05; ACS: acute coronary syndrome; CYP: cytochrome P450.</p

Path modelling results.

<p>ACS: acute coronary syndrome; BMI: body mass index; GFR: glomerular filtration rate; CYP: cytochrome P450; ABCB1: gene encoding transmembrane transporter P-glycoprotein; PON1: paroxonase 1; HTPR: high on treatment platelet reactivity; MACE: major adverse cardiac events (MACE: the composite of acute coronary syndrome, stent thrombosis and cardiac death).</p

Multiple Cox regression model for prediction major adverse cardiac events (MACE: the composite of acute coronary syndrome, stent thrombosis and cardiac death).

<p>HTPR: high on treatment platelet reactivity.</p

Survival analysis according to the high on treatment platelet reactivity (HTPR) and age.

<p>MACE: major adverse cardiac events: the composite of acute coronary syndrome, stent thrombosis and cardiac death; PCI: percutaneous coronary intervention.</p

Patient demographics.

<p>Data are reported as Mean ± standard deviation (SD), n (number of patients) or percentages; CAD: coronary artery disease; PCI: percutaneous coronary intervention; NSTE-ACS: non ST- elevation acute coronary syndrome, STEMI: ST- elevation myocardial infarction. ABCB1: gene encoding transmembrane transporter P-glycoprotein; PON1: paroxonase 1.</p

Univariate logistic regression for prediction of high on treatment platelet reactivity (HTPR).

<p>ACS: acute coronary syndrome; BMI: body mass index; GFR: glomerular filtration rate; CAD: coronary artery disease; CYP: cytochrome P450; ABCB1: gene encoding transmembrane transporter P-glycoprotein; PON1: paroxonase 1.</p

Incidence of increased % of patients with high on treatment platelet reactivity (HTPR) according to cumulative number of score variables.

<p>ACS: acute coronary syndrome; DM: diabetes mellitus; CYP: cytochrome P450.</p

Baseline characteristics of study participants.

<p>Baseline characteristics of study participants.</p

Platelet reactivity over time in STEMI and NSTEMI patients.

<p>Platelet reactivity evaluated with (A) the VASP assay and (B) Multiplate at baseline, and at 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, and 12 h after administration of a 180 mg ticagrelor loading dose in patients with STEMI and NSTEMI. NSTEMI: non-ST-elevation myocardial infarction, STEMI: ST-elevation myocardial infarction, VASP: vasodilator-stimulated phosphoprotein.</p